Official US documents have disclosed that a popular anti-stroke medicine may have used fictitious data while concealing research on its fatal effects. In 2009, the acclaimed British medical journal, The Lancet, published a prime story on rivaroxaban, a blood thinner medicine, which showed that the treatment was safe and efficient. But recently, the same journal warned of defaults in the trial data and claimed to initiate an investigation over it.

Lancet opens probe into ‘unreliable’ anti-stroke medicine

chemical-probes

Chemical Probes, News on Chemical Probes, stories on Chemical Probes, articles on Chemical Probes, Chemical Probes stories at Wion, Chemical Probes news, Chemical Probes latest news

chemical probes

Lancet opens probe into ‘unreliable’ anti-stroke medicine